<DOC>
	<DOCNO>NCT00292864</DOCNO>
	<brief_summary>The purpose study assess safety tolerability one-hour infusion give daily 5 consecutive day 21-day treatment cycle ; define recommend phase 2 dose ; learn clinical activity SNS-032 .</brief_summary>
	<brief_title>Safety Assessment One-hour Infusions SNS-032 Treatment Select Advanced Solid Tumors</brief_title>
	<detailed_description>Other objective study include measure pharmacokinetics ( long drug measure body ) , preliminary evaluation biomarkers see level certain protein change administration SNS-032 ; assessment effect SNS-032 QT interval .</detailed_description>
	<mesh_term>Cyclin-Dependent Kinase Inhibitor Proteins</mesh_term>
	<criteria>Able provide write informed consent Advanced , progress solid tumor cure In Stage 1 , advance solid malignancy In Stage 2 , advance breast cancer , melanoma , nonsmall cell lung cancer ( NSCLC ) Eastern Cooperative Oncology Group ( ECOG ) Performance Status score 0 , 1 , 2 Recovered radiation therapy may give last 21 day Recovered surgery Prior exposure SNS032 ( previously know BMS387032 ) Pregnant breastfeed Women male partner woman able child unwilling use approve , effective mean birth control Took part another clinical trial last 21 day Abnormal lab value serum potassium , hemoglobin , neutrophil , platelet , creatinine , AST , ALT , total bilirubin Brain metastasis , patient neurologically stable need corticosteroid anticonvulsant anytime within 28 day period enrollment . Other active malignancy Prior pelvic radiation therapy â‰¥ 25 % bone marrow reserve Any condition would keep patient safely take part clinical trial Please note : There additional inclusion/exclusion criterion study . Please contact study center additional information determine study criterion meet .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Tumor</keyword>
	<keyword>Advanced solid tumor</keyword>
</DOC>